BioSpace News Archive

Synchroneuron is no longer operating.

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for urgent unmet medical needs. The objective of Panbela’s pipeline is the utilization of pharmacotherapies to reduce/normalize increased disease-associated polyamines using complementary pharmacotherapies.

California Life Sciences (CLS) is the state’s most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline.

Biopact is a Molecular Rebar Design Company focusing on nanoscale biomaterials company developing the MGMR intracellular delivery vehicle. MGMR is a cellular-engineering tool for biomanufacturing and agricultural processes which value efficient delivery of RNAs, peptides, and genetic materials.

Nabsys, the pioneer of electronic genome mapping (EGM), uses solid-state nanodetectors to survey long DNA molecules to construct high-density maps with long-range information required to detect structural variants (SVs).

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for bacterial infections, including multi-drug resistant, or MDR, bacterial infections, and rare diseases.

Thyritope was launched as one of several collaborations between Avalon Ventures and GlaxoSmithKline (GSK)

Madrigal (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH).

Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars.

Dimension Therapeutics was acquired by Ultragenyx in 2017.